Skip to main content

Table 2 Summary of IHC analysis of IL32 in patient samples (TMA)

From: Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues

Pathology

Nature

Receptor status

# samples (Signal Intensity)

% with signal ≥ 3

Normal

Normal

Non triple negative

3/9 (1–2) ; 6/9 ND

0%

Fibroadenoma

Benign

Non triple negative

0/6 (0–1)

0%

Invasive ductal carcinoma with residual normal/hyperplasia

Benign

Non triple negative

1/1 (3)

100%

Atypical/Seveous atypical hyperplasia

Hyperplasia

Non triple negative

0/4 (0–1)

0%

Ductal carcinoma/Invasive ductal or lobular carcinoma

Malignant

Non triple negative

16/64 (3–4) ; 9 (1–2); 39/64 ND

25%

Invasive ductal carcinoma

Malignant

Triple negative

5/12 (3–4) ; 7/12 ND

42%

  1. The pathology, nature and receptor status were determined by the TMA vendor. Ninety four total cores demonstrated CD31 signal intensity ≥ 3, and subsequently included in the IHC analyses. The IL32 signal intensities were scored and the number of samples analyzed and their corresponding IL32 signal intensities listed. The percent of samples with IL32 signal intensities ≥ 3+ were also given. ND = not detected. The signal intensity determined by 2 operators (AP and TO).